Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement

Human Psychopharmacology

Volumn 18, Issue 1, 2003, Pages 29-38

  Montplaisir, J ^a   Hawa, R ^a   Moller, H ^a   Morin, C ^a   Fortin, M ^a   Matte, J ^a   Reinish, L ^a   Shapiro, Colin M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATROPINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORAL HYDRATE; CIMETIDINE; ERYTHROMYCIN; FLURAZEPAM; HYPNOTIC AGENT; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; KETOCONAZOLE; LORAZEPAM; METOCLOPRAMIDE; NEFAZODONE; NITRAZEPAM; PYRAZOLOPYRIMIDINE DERIVATIVE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THIORIDAZINE; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZALEPLON; ZOPICLONE;

ANTEROGRADE AMNESIA; CANADA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; DEPRESSION; DISTRESS SYNDROME; DOSE RESPONSE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; INSOMNIA; MALE; MEMORY DISORDER; MENTAL DISEASE; NIGHT SLEEP; NONREM SLEEP; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE;

ACETAMIDES; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CANADA; CONSENSUS; DRUG INTERACTIONS; DRUG UTILIZATION REVIEW; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES; PYRIMIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0037272830     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.445     Document Type: Review

References (88)

1. Adam K, Adamson L, Brezinova V, Hunter WM. 1976. Nitrazepam: lastingly effective but trouble on withdrawal. BMJ 26: 1558-1560.
2. Agnoli A, Manna V, Martucci N. 1989. Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia. Int J Clin Pharm Res 4: 277-281.
3. Allen D, Curran HV, Lader M. 1993. The effects of single doses of CL 284,846, lorazepam, and placebo on psychomotor function and memory function in normal male volunteers. Eur J Clin Pharmacol 45: 313-320.
4. American Psychiatric Association (APA). 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. APA: Washington, DC.
5. Ancoli-Israel X, Walsh JK, Mangano RM, Fujimoro M. Zaleplon. 1999. A novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. J Clin Psychiatry 1(4): 114-120.
6. Anderson AA. 1987. Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep 10(Suppl. 1): 54-62.
7. Autret E, Maillard F, Autret A. 1987. Comparison of the clinical hypnotic effects of zopiclone and triazolam. Eur J Clin Pharmacol 31: 621-623.
8. Azumi K, Shirakawa S. 1981. Characteristics of spindle activity and their use in evaluation of hypnotics. Sleep 5: 95-105.
9. Beer B, Clody DE, Mangano R, Levner M, Mayer, Barrett JE. 1997. A review of the preclinical development of zaleplon, a novel nonbenzodiazepine hypnotic for the treatment of insomnia. CNS Drug Rev 3: 207-224.
10. Benca RM. 2001. Consequences of insomnia and its therapies. J Clin Psychiatr 62(Suppl. 10): 33-38.
11. Bianchi M, Musch B. 1990. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 5(Suppl. 2): S139-S145.
12. Billiard M, Besset A, de Lustrac C, Buissand L. 1990. Dose response effects of zopiclone on night sleep and on night time and daytime functioning. Sleep 10(Suppl. 1): 27-34.
13. Buysse DJ, Reynolds CR, Kupfer DJ, et al. 1994. Clinical diagnosis in 216 insomnia patients using the international classification of sleep disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APANIMH DSM-IV field trial. Sleep 17: 630-637.
14. Chaudoir PJ, Bodkin NL, O'Donnel J, Anderson A, Holland RL. 1990. A comparative study of zopiclone and triazolam in patients with insomnia. Int Clin Psychopharmacol 5(Suppl. 2): S21-S27.
15. Clark TJH, Collins JV, Tong D. 1971. Respiratory depression caused by nitrazepam in patients with respiratory failure. Lancet II: 737-738.
16. Cohn M. 1983. Hypnotics and the control of breathing a review. Br J Clin Pharmacol 16(Suppl. 2): S245-S250.
17. Commiskey J, Guilleminault C, Del Rio G, Silvestri R. 1983. The effects of flurazepam on sleep studies in patients with chronic obstructive pulmonary disease. Chest 84: 143-147.
18. Compendium of Pharmaceuticals and Specialties, 34th edn. 1999. Canadian Pharmacist Association: Ottawa.
19. Curran HV. 1991. Benzodiazepines, memory and mood: a review. Psychopharmacology 105: 1-8.
20. Darwish M. 1999. Overview of drug-interaction studies with zaleplon. Sleep 22(Suppl.): S280.
21. Dietrich B, Farr I. 1995. Zaleplon: dose response evaluation in primary insomnia (abstract). Sleep Res 24A: 116.
22. Dolly FR, Block AJ. 1984. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic patients. AJM 73: 239-243.
23. Dooley M, Plosker GL. 2000. Zaleplon: a review of its use in the treatment of insomnia. Drugs 60: 413-445.
24. Elie R, Frenay M, Le Morvan P, et al. 1990. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 5(Suppl. 2): S39-S46.
25. Elie R, Ruther E, Farr I, Emilien G, Salinas E. 1999. Sleep latency is shortened during four weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 60: 536-544.
26. Feinberg I, Fein G, Walker JM, Price LJ, Floyd TC, March JD. 1977. Flurazepam effects on slow-wave sleep: stage 4 suppressed but number of delta waves constant. Science 198: 847-848.
27. Fleming JA, Bourgouin J, Hamilton P. 1988. A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can J Psychiatry 33: 103-107.
28. Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J. 1990. A comparison of the efficacy, safety, and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 5(Suppl. 2): S39-S46.
29. Ford DE, Kamerow DB. 1989. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? J Am Med Assoc 262: 1479-1484.
30. Fry J, Scharf M, Mangano R, Fujimoro M. 2000. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 15: 141-152.
31. Gaddie J, Legge JS, Palmer KNV, Petrie JC, Wood RA. 1972. Effect of nitrazepam in chronic obstructive bronchitis. BMJ 2: 688-689.
32. Gaillard JM, Schulz P, Tissot R. 1973. Effects of three benzodiazepines (nitrazepam, flunitrazepam and bromazepam) on sleep normal subjects, studied with an automatic sleep scoring system. Pharmacopsychiatry 6: 207-217.
33. Geddes DM, Rudolf M, Saunders KB. 1976. Effect of nitrazepam and flurazepam on the ventilatory response to carbon dioxide. Thorax 31: 548-551.
34. George CFP, Series F, Kryger MH, Moskovitch A. 1999. Safety and efficacy of zaleplon versus zolpidem in outpatients with chronic obstructive pulmonary disease (COPD) and insomnia (abstract). Sleep 22(Suppl.): S320.
35. Ghoneim MM, Mewaldt SP. 1990. Benzodiazepines and human memory: a review. Anesthesiology 72: 926-938.
36. Gillin JC, Spinweber CL, Johnson LC. 1989. Rebound insomnia: a critical review. J Clin Psychopharmacol 9: 161-172.
37. Gray J. 1998. Therapeutic Choices, 2nd edn. Canadian Pharmacists Association: 50.
38. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. 1998. Comparative kinetics and dynamics of zaleplon, zolpidem and placebo. Clin Pharmacol Ther 64: 553-561.
39. Guilleminault C. 1990. Benzodiazepines, breathing, and sleep. AJM 88(Suppl. 3A): S25-S28.
40. Hajak G. 1999. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years of clinical experience. Drug Safe 21: 457-469.
41. Hajak G, Clarenbach P, Fischer W, Haase W, Ruther E. 1994. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 9: 251-261.
42. Hedner J, Emilien G, Salinas E. 1998. Improvement in sleep latency and sleep quality with zaleplon in elderly patients with primary insomnia (abstract). J Sleep Res 7(Suppl. 2): S115.
43. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. 2000. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 162: 225-233.
44. Hurst M, Noble S. 1999. Zaleplon. CNS Drugs 11: 387-392.
45. Johnson LC, Hanson K, Bickford RG. 1976. Effect of flurazepam on sleep spindles and K-complexes. Electroenceph Clin Neurophysiol 40: 67-77.
46. Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL. 1987. Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol 27: 508-515.
47. Kales A, Manfredi RL, Vgontzas AW, Bixler EO, Vela-Bueno A, Fee EC. 1991. Clinical trials and therapeutics: rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 49: 468-476.
48. Kelly K. 1998. Waiting for sleep. Pharmacy Practice.
49. Kirkwood CK. 1999. Management of insomnia. J Am Pharmaceut Assoc 39(5): 688-696; quiz 713-714.
50. Klimm HD, Dreyfus JF, Delmotte M. 1987. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 10(Suppl. 1): S73-S78.
51. Lader M. 1997. Zopiclone: is there any dependence and abuse potential? J Neurol 244(Suppl. 1): S18-S22.
52. Lemoine P, Ohayon MM. 1997. Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? Prog Neuro-Psychopharmacol Biol Psychiatr 21: 111-124.
53. Lister RG. 1985. The amnesic action of benzodiazepines in man. Neurosci Biobehavi Rev 9: 87-94.
54. Lofaso F, Goldenberg F, Thebault C, Janus C, Harf A. 1997. Effect of zopiclone in sleep, night time ventilation and daytime vigilance in upper airway resistance syndrome. Eur Resp J 10: 2573-2577.
55. Lucki I, Rickets K, Geller A. 1986. Chronic use of benzodiazepines and psychomotor and cognitive performance. Psychopharmacology 88: 426-433.
56. Lundbeck Ltd. 2000. Sonata summary of product characteristics.
57. Mellinger GD, Balter MB, Uhlenhuth EH. 1985. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatr 42: 225-232.
58. Mendelson WB, Garnett D, Gillin C. 1981. Flurazepam-induced sleep apnea syndrome in a patient with insomnia and mild sleep-related respiratory changes. J Nerv Ment Dis 4: 261-264.
59. Midgren B, Hansson L, Skeidsvoll H, Elmqvist D. 1989. The effect of nitrazepam and flunitrazepam on oxygen desaturation during sleep in patients with stable hypoxemic non-hyercapnic COPD. Chest 95: 765-768.
60. Model DG. 1973. Nitrazepam induced respiratory depression in chronic obstructive lung disease. Br J Dis Chest 67: 128-130.
61. Ngen CC, Hassan R. 1990. A double-blind, placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol 5: 165-171.
62. Muir JF, de Fouilloy C, Broussier P, Locquet R, Maillard F. 1990. Comparative study of the effects of zopiclone and placebo on respiratory function in patients with chronic obstructive respiratory insufficiency. Int Clin Psychopharmacol (Suppl. 2): 85-94.
63. Musch B, Maillard F. 1990. Zopiclone the third generation of hypnotic: a critical review. Int Clin Psychopharmacol 5 (Suppl. 2): 147-158.
64. Noble S, Langtry HD, Lamb HM. 1998. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 55: 277-302.
65. O'Toole DP, Carlisle RJT, Howard PJ, Dundee JW. 1985. The influence of altered gastric emptying rates on orally administered zopiclone pharmacokinetics. Br J Clin Pharmacol 21: 615.
66. Parino L, Boselli M, Spaggiari MC, Smerieri A, Terziano MG. 1997. Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: polysomnographic analysis by means of cyclic alternating pattern. Clin Neuropharmacol 20: 253-263.
67. Pat-Horenczyk R, Hacohen D, Herer P, Lavie P. 1998. The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology 140: 450-457.
68. Pecknold J, Wilson R, le Morvan P. 1990. Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 5(Suppl. 2): S57-S67.
69. Ponciano E, Freitas F, Camara J, Faria M, Barretto M, Hindmarch I. 1990. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac patients. Int Clin Psychopharmacol 5(Suppl. 2): 69-77.
70. Rudolf M, Geddes DM, Turner JAM, Saunders KB. 1978. Depression of central respiratory drive by nitrazepam. Thorax 33: 97-100.
71. Rush CR, Frey JM, Griffiths RR. 1999. Zaleplon and triazolam in humans: behavioural effects and abuse potential. Psychopharmacology 145: 39-55.
72. Sanger DJ. 1995. Behavioural effects of novel benzodiazepine (w) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetrazole cue. Behav Pharmacol 6: 116-126.
73. Scharf MB, Fletcher K, Graham JP. 1988. Comparative amnestic effects of benzodiazepine hypnotic. J Clin Psychiatry 49(4): 134-137.
74. Servier Canada Inc. 2000. Starnoc Product Mongraph. Canada.
75. Shapiro CM, Sherman D, Peck DF. 1995. Withdrawal from benzodiazepines by initiating switching to zopiclone. Eur Psychiatr 10(Suppl. 3): 145-151.
76. Simon G, Von Korff M. 1997. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatr 154: 1417-1423.
77. Slyk MP. 2000. Drug interactions: the pharmacist's forte. The Consultant Pharmacist 15.
78. Tamminen T, Hansen PP. 1987. Chronic administration of zopiclone and nitrazepam in the treatment of insomnia. Sleep 10(Suppl. 1): S63-S72.
79. Troy SM, Lucki I, Unruh MA, et al. 2000. Comparison of the effects of zaleplon, zolpidem and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 20: 328-337.
80. Van der Kleijn E. 1989. Effects of zopiclone and temazepam on sleep, behaviour, and mood during the day. Eur J Clin Pharmacol 36: 247-251.
81. Vermeeren A, Danjou PE, O'Hanlon JF. 1998. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 13: S98-S107.
82. Vigilance-Clinique. 2000. Logiciel Clinique d'aide à la Décision. PQ. Canada.
83. Walsh JK, Fry J, Erwin CW, Scharf M, Roth T, Vogel G. 1998. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 16: 347-354.
84. Walsh JK, Vogel GW, Scharf M, et al. 2000. A five-week polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1: 41-49.
85. Warot D, Bensimon G, Danjou P, Puech AJ. 1987. Comparative effects of zopiclone, triazolam, and placebo on memory and psychomotor performance in healthy volunteers. Fundam Clin Pharmacol 1: 145-152.
86. Wickland C, Patat A. 1999a. The pharmacokinetics and safety of zaleplon in patients with renal impairment (abstract). Sleep Res 2(Suppl. 1): S172.
87. Wickland C, Patat A. 1999b. The safety and pharmacokinetics of zaleplon in hepatically impaired patients (abstract). Sleep Res 2(Suppl. 1): S171.
88. Wyeth-Ayerst. 1999. Sonata Prescribing Information. USA.